Dr. Jack West reviews the encouraging results with selumetinib,
a MEK inhibitor, in combination with chemotherapy for patients with
advanced NSCLC and a KRAS mutation, the most common molecular
marker seen in lung cancer.
About the Podcast
Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit cancerGRACE.org for more info.